Small Pharma Inc.

TSXV:DMT Stock Report

Market Cap: CA$50.4m

Small Pharma Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

George Tziras

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure1.3yrs
CEO ownershipn/a
Management average tenure1.3yrs
Board average tenure2.5yrs

Recent management updates

Recent updates

We're A Little Worried About Small Pharma's (CVE:DMT) Cash Burn Rate

Aug 26
We're A Little Worried About Small Pharma's (CVE:DMT) Cash Burn Rate

Can Small Pharma (CVE:DMT) Afford To Invest In Growth?

Feb 13
Can Small Pharma (CVE:DMT) Afford To Invest In Growth?

Here's Why We're Watching Small Pharma's (CVE:DMT) Cash Burn Situation

Oct 30
Here's Why We're Watching Small Pharma's (CVE:DMT) Cash Burn Situation

CEO Compensation Analysis

How has George Tziras's remuneration changed compared to Small Pharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Aug 31 2023n/an/a

-CA$19m

May 31 2023n/an/a

-CA$23m

Feb 28 2023n/an/a

-CA$23m

Nov 30 2022n/an/a

-CA$25m

Aug 31 2022n/an/a

-CA$23m

May 31 2022n/an/a

-CA$20m

Feb 28 2022CA$403kCA$337k

-CA$22m

Nov 30 2021n/an/a

-CA$21m

Aug 31 2021n/an/a

-CA$18m

May 31 2021n/an/a

-CA$15m

Feb 28 2021CA$66kCA$66k

-CA$7m

Compensation vs Market: Insufficient data to establish whether George's total compensation is reasonable compared to companies of similar size in the Canadian market.

Compensation vs Earnings: George's compensation has increased whilst the company is unprofitable.

CEO

George Tziras

1.3yrs

Tenure

CA$402,552

Compensation

Mr. George Tziras serevs as Chief Business Officer & Director at Cybin Inc. since October 2023. He served as Chief Business Officer of Small Pharma Inc. since January 2021 until July 2022 and also serves a...

Leadership Team

NamePositionTenureCompensationOwnership
George Tziras
CEO & Non-Independent Director1.3yrsCA$402.55kno data
David Steel
Chief Financial Officer2.8yrsCA$392.92k0%
CA$ 0
Carol Routledge
Chief Scientific & Medical Officer3.3yrsCA$491.59kno data
Marie Layzell
Chief Manufacturing & Development Officer & Director1.3yrsCA$464.44k0%
CA$ 0
Alastair Riddell
Chief Operating Officer1.3yrsno data0%
CA$ 0
Jenny Maguire
Head of Brand & Communications1.1yrsno datano data
Emma Hodge
Head of Intellectual Property2.8yrsno datano data
Richard Kimel
Corporate Secretaryno datano datano data
Sarah Hamilton
Group Financial Controller1.3yrsno datano data
Jim Rennie
Director of Development and Member of Scientific & Advisory Board7.4yrsno datano data

1.3yrs

Average Tenure

56yo

Average Age

Experienced Management: DMT's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
George Tziras
CEO & Non-Independent Director2.5yrsCA$402.55kno data
Marie Layzell
Chief Manufacturing & Development Officer & Director2.5yrsCA$464.44k0%
CA$ 0
Jim Rennie
Director of Development and Member of Scientific & Advisory Board6.3yrsno datano data
Paul Maier
Non-Executive Independent Director1.9yrsCA$21.43kno data
Michael Wolfe
Independent Director2.5yrsCA$62.98k0%
CA$ 0
Lyne Fortin
Non-Executive Independent Chairman2.5yrsCA$93.96k0%
CA$ 0
Lorna Griffin
Member of Scientific & Advisory Board6.3yrsno datano data
Alan Armstrong
Member of Scientific & Advisory Board6.3yrsno datano data

2.5yrs

Average Tenure

60yo

Average Age

Experienced Board: DMT's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/10/26 04:10
End of Day Share Price 2023/10/20 00:00
Earnings2023/08/31
Annual Earnings2023/02/28

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Small Pharma Inc. is covered by 5 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Tania Armstrong-WhitworthCanaccord Genuity
Elemer PirosD. Boral Capital LLC.
Sepehr ManochehryEight Capital